New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Vinay Prasad
US hematologist–oncologist
Nothing else this week.
Related events
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Research advances have led to the approval of new therapies by the FDA.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- FDA approval expands patient access to therapies for ACCORD.
Coverage
Newest first; wire copies grouped- BloombergFDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink (Bloomberg) -- Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the bio